PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

• 批准号: 6489030
• 负责人: FAITH H KUNG
• 金额: $ 4.39万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-07-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6489030
• 关键词: 6 thiopurine; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tissue resource /registry; topotecan; trimetrexate; vincristine

This proposal represents a request to support continued participation in the pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic, immunological and molecular biological approaches to the treatment of acute leukemia and other neoplastic diseases of childhood. Significant disease free survival has been achieved and contributions have been made in clinical pharmacology, tumor immunology and biology of cancer. However the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests new avenues to be explored in new protocols. POG led in the investigation in the immunophenotyping of acute lymphoblastic leukemia, NTX polyglutamates accumulation in leukemic cells, and N-myc gene amplication in neuroblastoma, correlated the findings with patient outcome, and then incorporated them in new treatment protocols designed to improve the survival of children with cancer. The Division of pediatric Hematology/Oncology at the University of California, San Diego has 24 years experience (10 years in CALGB and 14 in POG) in cooperative clinical trials. In the past 5 years the 4 consortium member institutions had entered 332 patients on both therapeutic and non- therapeutic studies and the satellites, 211 patients. Our investigators served on 12 committees, designed/coordinated 16 group protocol studies. We also contributed to 15 group publications/presentations. Our investigators will continue to design and chair therapeutic protocols,and serve on committees. Dr. Yu's laboratory will continue to explore new immunotherapeutic agents for Group use, and serve as the Group Reference Laboratory. We plan to continue our active participation in all phases of POG activities.

这项提议是要求支持继续参与

项目成果

Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.

脱氧考福霉素治疗第二次缓解早期儿童 T 细胞急性淋巴细胞白血病：一项儿科肿瘤学小组研究。

• DOI: 10.1002/mpo.2950160507
• 发表时间: 1988
• 期刊: Medical and pediatric oncology
• 作者: Winick,N;Buchanan,GR;Murphy,SB;Yu,A;Boyett,J
• 通讯作者: Boyett,J

Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group.

依托泊苷（VP-16）治疗儿童复发性恶性实体瘤的临床试验。

• DOI: 10.1007/bf00170776
• 发表时间: 1988
• 期刊: Investigational new drugs
• 影响因子: 3.4
• 作者: Kung,F;Hayes,FA;Krischer,J;MahoneyJr,D;Leventhal,B;Brodeur,G;Berry,DH;Dubowy,R;Toledano,S
• 通讯作者: Toledano,S

Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: a Pediatric Oncology Group pilot study (9139).

脑干肿瘤中的超分割照射和同步顺铂：一项儿科肿瘤学小组试点研究 (9139)。

• DOI: 10.1159/000120794
• 发表时间: 1994
• 期刊: Pediatric neurosurgery
• 影响因子: 0.7
• 作者: Kadota,RP;Mandell,LR;Fontanesi,J;Kovnar,EH;Krischer,J;Kun,LE;Friedman,HS
• 通讯作者: Friedman,HS

Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro.

使用丙氨酸作为甲硫腺苷磷酸化酶选择性疗法在体外治疗 T 细胞急性淋巴细胞白血病。

• 发表时间: 1999
• 期刊: Cancer research.
• 作者: Batova,A;Diccianni,MB;Omura-Minamisawa,M;Yu,J;Carrera,CJ;Bridgeman,LJ;Kung,FH;Pullen,J;Amylon,MD;Yu,AL
• 通讯作者: Yu,AL

Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia.

• DOI: 10.1182/blood.v84.9.3105.bloodjournal8493105
• 发表时间: 1994-11
• 期刊: Blood
• 影响因子: 20.3
• 作者: M. Diccianni;Jennifer C. Yu;M. Hsiao;S. Mukherjee;Shaohua Le;A. Yu